Blood Screening Market
Industry
- Automobile and Transportation
- Chemicals and Materials
- Consumer Goods
- Energy and Power
- Electronics and Semiconductor
- Food and Beverages
- Machinery and Equipment
- Pharma and Healthcare
- Service and Software
- Others
- Packaging
- ICT
- Technology
- Medical Devices and Consumables
- Agriculture
- Medical Care
- Aerospace and Defense
Blood Screening Market Size, Share & Analysis By Product (Instruments, Kits and Reagents), By Technology (NAT Technology, Immunoassays), By End-Use (Blood Banks, Hospitals, Pathology Laboratories), By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa), and Growth Forecast To 2032
Report ID: RV77471 | Published: Feb 2024 | Historical Period: 2018-2022 | Pages: 190 | Price: $3260| Industry: Medical Care
Blood Screening Market Overview 2024:
The blood screening market was USD 2 billion in 2023 and is expected to register a rapid CAGR of 7% during the forecast period. Key factors such as increasing blood donations across the globe, growing prevalence of blood-borne diseases, and steadily growing healthcare infrastructure are expected to drive global market growth over the forecast period.
Blood screening is a key aspect of the healthcare sector, providing valuable information for diagnosis and treatment planning. It is a process that involves testing and analyzing blood samples for assessing various parameters or identifying potential health risks.
Blood transfusion uses different technologies such as TMA, real-time PCR, NGS, immunoassays, enzyme immunoassays, chemiluminescent immunoassays, particle agglutination assays, rapid assays, Western blot, and ELSA. Its primary objective is to ensure the safety of blood products intended for transfusion, identify and monitor health conditions, and contribute to disease prevention and early diagnosis.
Blood screening typically involves a range of tests such as complete blood count, blood typing, cross-matching, liver and kidney function tests, coagulation, and genetic testing that can assess different aspects of blood like its cellular components, chemistry, and presence of infectious agents. Various types of blood screening tools and equipment are deployed in large-scale hospitals, blood banks, and laboratories.
However, high initial investments and inadequate healthcare infrastructure and resources can hamper the widespread adoption of advanced blood screening tools in budget-constrained healthcare centers.
Graphical Overview:
Key Takeaways:
Rising Incidence of Blood-Borne Diseases:
The rising prevalence of different types of blood-borne diseases such as malaria, HIV, syphilis, and hepatitis has increased the need for advanced blood screening tools and kits. This is expected to drive global market growth during the forecast period. Moreover, increasing awareness about importance of early detection and diagnosis and government efforts to promote blood screening are expected to boost market growth going ahead.
High Costs Associated with Advanced Blood Screening Technologies:
The initial costs associated with implementing and maintaining advanced blood screening technologies are high which can limit its adoption, especially in small healthcare facilities due to budget restraints. In addition, availability of alternative technologies for blood screening is expected to hamper overall market growth during the forecast period.
Type Outlook:
By product, the global market is segmented into instruments, kits and reagents. Among these, the kits and reagents segment is expected to account for the largest revenue share between 2024 and 2032 owing to rising prevalence of various blood-borne diseases, need for different types of kits and reagents to detect various diseases and health issues, and increasing investments in development of advanced kits and reagents.
End Use Outlook:
Based on end use, the global market is segmented into blood banks, hospitals, and pathology laboratories. The blood banks segment is expected to register rapid revenue CAGR over the forecast period. This can be attributed to rising blood donations across the globe, increasing number of blood banks, and high usage of blood screening tools and techniques for the detection of infectious agents, ensuring blood safety, minimizing transfusion-related risks and early detection of emerging pathogens.
Regional Outlook:
North America is expected to account for the largest revenue share in the global market during the forecast period owing to rising prevalence of blood-borne diseases, rapid advancements in screening technology, and growing demand for blood transfusions. Moreover, presence of leading key players and well-established healthcare facilities, and growing awareness about early detection and diagnosis are other factors expected to drive North America market growth between 2024 and 2032.
Report Coverage:
| Report Details | Outcome |
| Base Year for Estimation | 2023 |
| Historical Data | 2018-2022 |
| Forecast Period | 2024-2032 |
| Segments Covered: | Product, Technology, End-Use, and Region |
| By Product | Instruments, Kits and Reagents |
| By Technology | NAT Technology, Immunoassays |
| By End Use | Blood Banks, Hospitals, Pathology Laboratories |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Country Scope | United States, Canada, Germany, France, UK, Italy, Russia, China, Japan, South Korea, Southeast Asia, India, Mexico, Brazil, Saudi Arabia, UAE, Turkey |
| Qualitative Info | •Value Chain Analysis •Pricing Analysis •Regional Outlook •Market Trends •Market Share Analysis •Competition Analysis •Technological Advancements |
| Key Players | Abbott Laboratories, Bio-Rad Laboratories, Inc., DiaSorin S.p.A., Avioq, Inc., Danaher Corporation, Siemens AG, QuidelOrtho Corporation., Alive DX, Grifols, S.A., F. Hoffmann-La Roche Ltd. |
| Customization Scope | 10 Hours of Free Customization and Expert Consultation |
Competitive Landscape:
The global blood screening market is extremely competitive, comprising several regional and global level key players. Leading key players are focused on adopting various strategic alliances like mergers and acquisitions, partnerships, joint ventures, collaborations, and product launches to maintain their global position and enhance their product offerings. They are also focused on innovation, and scalability, and are adapting to evolving technology trends and consumer needs.
Some Leading Market Companies Listed in the Report:
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- DiaSorin S.p.A.
- Avioq, Inc.
- Danaher Corporation
- Siemens AG
- QuidelOrtho Corporation
- Alive DX
- Grifols, S.A.
- Hoffmann-La Roche Ltd.
Blood Screening Industry Recent Developments:
- In November 2023, Guardant Health, Inc., a leading company in precision oncology announced the launch of a Shield blood-based screening test for colorectal cancer.
- In November 2023, Roswell Park launched high-speed blood cancer tests.
- In June 2021, Grail announced the launch of the Galleri blood test, its groundbreaking multi-cancer screening diagnostic.
The global blood screening market has been segmented based on product, technology, end-use, and region:
By Product:
- Instruments
- Kits and Reagents
By Technology:
- NAT Technology
- Transcription Medicated Amplification (TMA)
- Real-time PCR
- NGS
- Immunoassays
- Enzyme Immunoassays
- Chemiluminescent Immunoassays
- Particle Agglutination Assays
- Rapid Assays
- Western Blot
- ELSA
By End Use:
- Blood Banks
- Hospitals
- Pathology Laboratories
By Region:
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Asia Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Frequently Asked Questions!
- Abbott Laboratories
- Bio-Rad Laboratories, Inc.
- DiaSorin S.p.A.
- Avioq, Inc.
- Danaher Corporation
- Siemens AG
- QuidelOrtho Corporation
- Alive DX
- Grifols, S.A.
- F. Hoffmann-La Roche Ltd.
To Learn More About This Report
Our Clients
